CL2021002575A1 - Compuestos de pirrol - Google Patents
Compuestos de pirrolInfo
- Publication number
- CL2021002575A1 CL2021002575A1 CL2021002575A CL2021002575A CL2021002575A1 CL 2021002575 A1 CL2021002575 A1 CL 2021002575A1 CL 2021002575 A CL2021002575 A CL 2021002575A CL 2021002575 A CL2021002575 A CL 2021002575A CL 2021002575 A1 CL2021002575 A1 CL 2021002575A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutically acceptable
- pyrrole compounds
- formula
- methods
- acceptable salts
- Prior art date
Links
- 150000003233 pyrroles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/094—Esters of phosphoric acids with arylalkanols
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente descripción se proporcionan compuestos de la Fórmula (I), o sales farmacéuticamente aceptables de estos, las composiciones farmacéuticas que incluyen un compuesto descrito en la presente descripción (que incluye sales farmacéuticamente aceptables de un compuesto descrito en la presente descripción) y métodos para sintetizarlas. En la presente descripción también se proporcionan métodos para tratar enfermedades y/o afecciones con un compuesto de la Fórmula (I), o una sal farmacéuticamente aceptable de este.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962828919P | 2019-04-03 | 2019-04-03 | |
US201962932686P | 2019-11-08 | 2019-11-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021002575A1 true CL2021002575A1 (es) | 2022-04-29 |
Family
ID=72667046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021002575A CL2021002575A1 (es) | 2019-04-03 | 2021-10-01 | Compuestos de pirrol |
Country Status (17)
Country | Link |
---|---|
US (3) | US11191747B2 (es) |
EP (1) | EP3947349A4 (es) |
JP (1) | JP2022522312A (es) |
KR (1) | KR20220004996A (es) |
CN (1) | CN114258391A (es) |
AU (1) | AU2020253444A1 (es) |
BR (1) | BR112021019817A2 (es) |
CA (1) | CA3134635A1 (es) |
CL (1) | CL2021002575A1 (es) |
CO (1) | CO2021014210A2 (es) |
IL (1) | IL286902A (es) |
MA (1) | MA55564A (es) |
MX (1) | MX2021012105A (es) |
PE (1) | PE20220252A1 (es) |
SG (1) | SG11202110718PA (es) |
TW (1) | TW202102474A (es) |
WO (1) | WO2020205934A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114685514A (zh) * | 2020-12-29 | 2022-07-01 | 广东东阳光药业有限公司 | 新型酰胺吡咯类化合物及其在药物中的应用 |
CN114805362A (zh) * | 2021-01-22 | 2022-07-29 | 广东东阳光药业有限公司 | 新型酰胺吡咯类化合物及其在药物中的用途 |
CN116768776A (zh) * | 2022-03-17 | 2023-09-19 | 成都微芯药业有限公司 | 吡咯酰胺类化合物及其制备方法和用途 |
CN116120219A (zh) * | 2022-12-27 | 2023-05-16 | 吉斯凯(苏州)制药有限公司 | 一种多取代吡咯类化合物及其制备方法和在制备hbv衣壳蛋白抑制剂中的应用 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4784782A (en) | 1986-03-27 | 1988-11-15 | The Lubrizol Corporation | Heterocyclic compounds useful as additives for lubricant and fuel compositions |
CA2415965A1 (en) | 2000-07-17 | 2002-01-24 | Ranbaxy Laboratories Limited | Oxazolidinone derivatives as antimicrobials |
ATE427948T1 (de) | 2001-04-24 | 2009-04-15 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
US6956040B2 (en) | 2001-07-16 | 2005-10-18 | Ranbaxy Laboratories Limited | Oxazolidinone piperazinyl derivatives as potential antimicrobials |
GB0119172D0 (en) | 2001-08-06 | 2001-09-26 | Melacure Therapeutics Ab | Phenyl pyrrole derivatives |
AU2003297398B2 (en) | 2002-12-20 | 2009-09-24 | Amgen Inc. | Asthma and allergic inflammation modulators |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
GB2398299A (en) | 2003-02-13 | 2004-08-18 | Melacure Therapeutics Ab | Pharmaceutically active phenyl-pyrrole derivatives |
US20070191336A1 (en) | 2003-12-24 | 2007-08-16 | Flynn Daniel L | Anti-inflammatory medicaments |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7745473B2 (en) | 2004-03-13 | 2010-06-29 | Kyoto University | Indole derivative for alkylating specific base sequence of DNA and alkylating agent and drug containing the derivative |
US20060105355A1 (en) | 2004-11-18 | 2006-05-18 | Karl Maurer | Electrode array device having an adsorbed porous reaction layer having a linker moiety |
US20060102471A1 (en) | 2004-11-18 | 2006-05-18 | Karl Maurer | Electrode array device having an adsorbed porous reaction layer |
WO2006092059A1 (en) | 2005-03-04 | 2006-09-08 | Fan Wu | Design and synthesis of novel antimicrobials |
US20100234379A1 (en) | 2005-07-28 | 2010-09-16 | Bahr Ben A | Dual modulation of endocannabinoid transport and fatty-acid amide hydrolase for treatment of excitotoxicity |
US20070065877A1 (en) | 2005-09-19 | 2007-03-22 | Combimatrix Corporation | Microarray having a base cleavable succinate linker |
CA2662902C (en) | 2006-09-15 | 2015-11-24 | Xcovery, Inc. | Kinase inhibitor compounds |
EP2155720B1 (en) | 2007-06-08 | 2013-07-17 | Advinus Therapeutics Private Limited | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application |
KR20100020478A (ko) | 2007-06-18 | 2010-02-22 | 사노피-아벤티스 | P2y12 길항제로서의 피롤 유도체 |
CA2754492A1 (en) | 2009-03-05 | 2010-09-10 | Purdue Research Foundation | Method for early imaging of atherosclerosis |
ES2528946T3 (es) | 2009-03-20 | 2015-02-13 | University Of Virginia Patent Foundation | Benzotiofeno-nitrotiazolida y otros antimicrobianos de amplio espectro |
EP2490529A4 (en) | 2009-10-22 | 2013-08-28 | Univ Vanderbilt | ALLOSTERIC POTENTIALIZERS OF MGLUR4, COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DYSFUNCTION |
SG185414A1 (en) | 2010-05-12 | 2012-12-28 | Univ Vanderbilt | Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
CN103068814B (zh) | 2010-06-15 | 2015-11-25 | 拜耳知识产权有限责任公司 | 邻氨基苯甲酸衍生物 |
CN104478800A (zh) | 2010-09-14 | 2015-04-01 | 波兰科学院生物化学与生物物理研究所 | 作为突变cftr蛋白的调节剂的化合物及其在治疗与cftr蛋白失常相关的疾病中的用途 |
WO2012047525A2 (en) | 2010-09-27 | 2012-04-12 | Endocyte, Inc. | Folate conjugates for treating inflammation of the eye |
US20120214824A1 (en) | 2010-12-08 | 2012-08-23 | Bradley Tait | Proteostasis regulators |
WO2012087976A2 (en) | 2010-12-21 | 2012-06-28 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
WO2012154880A1 (en) | 2011-05-09 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases |
WO2012154888A1 (en) | 2011-05-09 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Compounds for treating protein folding disorders |
EP2707101B1 (en) | 2011-05-12 | 2019-02-13 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
US8835640B1 (en) | 2011-11-16 | 2014-09-16 | Paresh T. Gandhi | Nicotine derivatives |
EP2804605A4 (en) | 2012-01-20 | 2015-07-08 | Acucela Inc | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES |
US9364460B2 (en) | 2012-09-19 | 2016-06-14 | Douglas V. Faller | PKC delta inhibitors for use as therapeutics |
TR201807090T4 (tr) * | 2013-07-25 | 2018-06-21 | Janssen Sciences Ireland Uc | Glioksamid sübstitüeli pirrolamid deriveleri ve bunun hepatitin tedavisine yönelik ilaçlar olarak kullanımı. |
CN104672221B (zh) | 2013-11-29 | 2018-01-23 | 中国科学院上海有机化学研究所 | 一种氟代苯并杂环‑杂芳环结构的合成方法 |
US10040780B2 (en) | 2014-03-03 | 2018-08-07 | The Regents Of The University Of California | Mcl-1 antagonists |
DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
US20160166679A1 (en) | 2014-12-12 | 2016-06-16 | Purdue Research Foundation | Method of treatment using folate conjugates and tyrosine kinase inhibitors |
KR101726059B1 (ko) | 2015-07-28 | 2017-04-12 | 한양대학교 산학협력단 | 디피롤 유도체와 암모늄 염을 포함하는 브롬화수소 가스 검출용 조성물 및 이를 포함하는 브롬화수소 가스 검출용 색변환 센서 |
KR101726060B1 (ko) | 2015-07-28 | 2017-04-12 | 한양대학교 산학협력단 | 디피롤 유도체와 금속 염을 포함하는 염화수소 가스 검출용 조성물 및 이를 포함하는 염화수소 가스 검출용 색변환 센서 |
US20180282331A1 (en) | 2015-11-09 | 2018-10-04 | Wockhardt Limited | 7-Oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections (changed by PCT to: 7-OXO -6-(SULFOOXY)- 1,6-DIAZABICYCLO [3.2.1] OCTANE CONTAINING COMPOUNDS AND THEIR USE IN TREATMENT OF BACTERIAL INFECTIONS |
JP7126947B2 (ja) * | 2016-03-09 | 2022-08-29 | エモリー ユニバーシティー | 抗ウイルス剤によるb型肝炎ウイルスの排除 |
JOP20190024A1 (ar) * | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
CN108250121A (zh) * | 2016-12-28 | 2018-07-06 | 上海长森药业有限公司 | 磺酰胺-芳基酰胺类化合物及其治疗乙型肝炎的药物用途 |
CN113166115A (zh) | 2018-10-05 | 2021-07-23 | 埃默里大学 | 单体和多聚体抗hbv药剂 |
JP2022521081A (ja) * | 2019-02-22 | 2022-04-05 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Hbv感染若しくはhbv誘導性疾患の治療において有用なアミド誘導体 |
-
2020
- 2020-04-01 PE PE2021001658A patent/PE20220252A1/es unknown
- 2020-04-01 JP JP2021559054A patent/JP2022522312A/ja active Pending
- 2020-04-01 BR BR112021019817A patent/BR112021019817A2/pt unknown
- 2020-04-01 US US16/837,515 patent/US11191747B2/en active Active
- 2020-04-01 SG SG11202110718PA patent/SG11202110718PA/en unknown
- 2020-04-01 KR KR1020217035886A patent/KR20220004996A/ko unknown
- 2020-04-01 EP EP20784496.0A patent/EP3947349A4/en active Pending
- 2020-04-01 AU AU2020253444A patent/AU2020253444A1/en active Pending
- 2020-04-01 MA MA055564A patent/MA55564A/fr unknown
- 2020-04-01 WO PCT/US2020/026116 patent/WO2020205934A1/en active Application Filing
- 2020-04-01 CN CN202080028131.4A patent/CN114258391A/zh active Pending
- 2020-04-01 CA CA3134635A patent/CA3134635A1/en active Pending
- 2020-04-01 MX MX2021012105A patent/MX2021012105A/es unknown
- 2020-04-01 TW TW109111398A patent/TW202102474A/zh unknown
-
2021
- 2021-10-01 CL CL2021002575A patent/CL2021002575A1/es unknown
- 2021-10-03 IL IL286902A patent/IL286902A/en unknown
- 2021-10-25 CO CONC2021/0014210A patent/CO2021014210A2/es unknown
- 2021-11-16 US US17/455,178 patent/US11771680B2/en active Active
-
2023
- 2023-08-22 US US18/453,887 patent/US20230390242A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202102474A (zh) | 2021-01-16 |
CN114258391A (zh) | 2022-03-29 |
PE20220252A1 (es) | 2022-02-16 |
MA55564A (fr) | 2022-02-09 |
JP2022522312A (ja) | 2022-04-15 |
WO2020205934A1 (en) | 2020-10-08 |
CA3134635A1 (en) | 2020-10-08 |
US20200323821A1 (en) | 2020-10-15 |
SG11202110718PA (en) | 2021-10-28 |
US20220071957A1 (en) | 2022-03-10 |
EP3947349A4 (en) | 2022-11-23 |
MX2021012105A (es) | 2021-11-03 |
AU2020253444A1 (en) | 2021-10-14 |
EP3947349A1 (en) | 2022-02-09 |
US20230390242A1 (en) | 2023-12-07 |
US11191747B2 (en) | 2021-12-07 |
CO2021014210A2 (es) | 2022-01-17 |
IL286902A (en) | 2021-10-31 |
BR112021019817A2 (pt) | 2021-12-07 |
US11771680B2 (en) | 2023-10-03 |
KR20220004996A (ko) | 2022-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021014210A2 (es) | Compuestos de pirrol | |
BR112022025037A2 (pt) | Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus | |
AR116604A1 (es) | Inhibidores de kras g12c | |
CO2024001367A2 (es) | Compuestos antivirales | |
CY1120080T1 (el) | Φαρμακευτικη συνθεση περιεχουσα εναν αναστολεα hdac και εναν κυκλοπολυσακχαριτη | |
CY1117085T1 (el) | C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης | |
DOP2024000039A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
PH12020552017A1 (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
CO2022002804A2 (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos | |
EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
CO2021002976A2 (es) | Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak | |
MX2020003993A (es) | Derivados de bencimidazol y sus usos. | |
BR112016013618A8 (pt) | derivados de maleimida como moduladores de série de reação de wnt, seus usos, composição farmacêutica e processo para a preparação dos mesmos | |
CL2022002975A1 (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
BR112021011325A2 (pt) | Derivados de rapamicina | |
CL2022001741A1 (es) | Compuestos cíclicos y métodos de uso de estos | |
BR112023018839A2 (pt) | Composto de glutarimida substituído por anel fundido com furano | |
DOP2021000254A (es) | Compuestos de pirrolidina | |
CO2021017202A2 (es) | Compuestos tricíclicos | |
UY38567A (es) | Inhibidores de o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa de éter bicíclico | |
AR126251A1 (es) | Inhibidores de cdk2 | |
AR119317A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
EA202192051A1 (ru) | Селективный ингибитор протеин-аргинин-метилтрансферазы 5 (prmt5) | |
BR112020026507A8 (pt) | Composto de isotiazolo[5,4-d]pirimidinas como inibidor de irak4 | |
AR128100A1 (es) | Compuestos para el tratamiento de la pérdida del cabello |